Sophia Wang1,2, Heidi Lindroth3,4,5, Carol Chan6, Ryan Greene1, Patricia Serrano-Andrews7, Sikandar Khan3,4,5, Gabriel Rios8, Shiva Jabbari9, Joanna Lim, Andrew J Saykin2,10, Babar Khan3,4,5. 1. Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana. 2. Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana. 3. Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 4. IU Center of Aging Research, Regenstrief Institute, Indianapolis, Indiana. 5. Center for Health Innovation and Implementation Science, Indianapolis, Indiana. 6. Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland. 7. Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee. 8. Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, Indiana. 9. Department of Pathology, Washington University, St. Louis, Missouri. 10. Department of Radiology, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
OBJECTIVES: To identify whether delirium biomarkers aligned with the National Institute on Aging-Alzheimer's Association (NIA-AA) research framework, a conceptual model that describes the use of diagnostic biomarkers for Alzheimer's disease and other related dementias (ADRD). DESIGN: Systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. SETTING: Acute care and outpatient settings. PARTICIPANTS: Adults diagnosed with delirium. METHODS AND MEASUREMENTS: MEDLINE, PsycInfo, Embase, and the Cochrane Library were searched for English-language studies published from January 2010 to February 2020. Studies included adults older than 18 years, identified delirium with a standardized assessment tool, and measured an ADRD biomarker. Independent reviewers determined whether an association between delirium and ADRD biomarker was found, the quality of biomarker data based on the REMARK (REporting recommendations for tumor MARKer prognostic studies) checklist, and the study bias based on the Newcastle-Ottawa Scale. RESULTS: A total of 61,256 citations were identified; 113 studies were included. Most studies did not examine amyloid, tau, or neurodegeneration biomarkers. Delirium may be associated with neurodegeneration biomarkers, but few to no studies found an association with amyloid and tau biomarkers. Delirium was not consistently associated with inflammatory biomarkers. The quality of biomarker data was moderate, and the risk of bias was moderate to high. Studies often did not collect prehospital and posthospital cognitive data. CONCLUSION: Most delirium diagnostic biomarker studies did not measure amyloid, tau, and/or neurodegenerative biomarkers, making characterization of the relationship between delirium and ADRD difficult. Future delirium biomarker diagnostic studies could improve the understanding of pathophysiologic links between delirium with other conditions affecting cognition.
OBJECTIVES: To identify whether delirium biomarkers aligned with the National Institute on Aging-Alzheimer's Association (NIA-AA) research framework, a conceptual model that describes the use of diagnostic biomarkers for Alzheimer's disease and other related dementias (ADRD). DESIGN: Systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. SETTING: Acute care and outpatient settings. PARTICIPANTS: Adults diagnosed with delirium. METHODS AND MEASUREMENTS: MEDLINE, PsycInfo, Embase, and the Cochrane Library were searched for English-language studies published from January 2010 to February 2020. Studies included adults older than 18 years, identified delirium with a standardized assessment tool, and measured an ADRD biomarker. Independent reviewers determined whether an association between delirium and ADRD biomarker was found, the quality of biomarker data based on the REMARK (REporting recommendations for tumor MARKer prognostic studies) checklist, and the study bias based on the Newcastle-Ottawa Scale. RESULTS: A total of 61,256 citations were identified; 113 studies were included. Most studies did not examine amyloid, tau, or neurodegeneration biomarkers. Delirium may be associated with neurodegeneration biomarkers, but few to no studies found an association with amyloid and tau biomarkers. Delirium was not consistently associated with inflammatory biomarkers. The quality of biomarker data was moderate, and the risk of bias was moderate to high. Studies often did not collect prehospital and posthospital cognitive data. CONCLUSION: Most delirium diagnostic biomarker studies did not measure amyloid, tau, and/or neurodegenerative biomarkers, making characterization of the relationship between delirium and ADRD difficult. Future delirium biomarker diagnostic studies could improve the understanding of pathophysiologic links between delirium with other conditions affecting cognition.
Authors: Terry E Goldberg; Chen Chen; Yuanjia Wang; Eunice Jung; Antoinette Swanson; Caleb Ing; Paul S Garcia; Robert A Whittington; Vivek Moitra Journal: JAMA Neurol Date: 2020-11-01 Impact factor: 18.302
Authors: Brian J Anderson; Christopher F Chesley; Miranda Theodore; Colin Christie; Ryan Tino; Alex Wysoczanski; Kristy Ramphal; Michelle Oyster; Laurel Kalman; Mary K Porteous; Christian A Bermudez; Edward Cantu; Dennis L Kolson; Jason D Christie; Joshua M Diamond Journal: J Heart Lung Transplant Date: 2018-02-02 Impact factor: 10.247
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02
Authors: Koen S Simons; Mark van den Boogaard; Eva Hendriksen; Jelle Gerretsen; Johannes G van der Hoeven; Peter Pickkers; Cornelis P C de Jager Journal: Crit Care Date: 2018-05-25 Impact factor: 9.097
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Maribel Torres-Velázquez; Margaret Parker; Amber Bo; Marissa White; Sean Tanabe; Robert A Pearce; Richard Lennertz; Steve Y Cho; Barbara Bendlin; Sterling C Johnson; Vivek Prabhakaran; Alan B McMillan; Robert D Sanders Journal: Br J Anaesth Date: 2022-01-04 Impact factor: 9.166
Authors: Sophia Wang; Ryan Greene; Yiqing Song; Carol Chan; Heidi Lindroth; Sikandar Khan; Gabriel Rios; Robert D Sanders; Babar Khan Journal: Int Psychogeriatr Date: 2022-01-17 Impact factor: 7.191
Authors: Carol K Chan; Yiqing Song; Ryan Greene; Heidi Lindroth; Sikandar Khan; Gabriel Rios; Babar Khan; Sophia Wang Journal: Am J Crit Care Date: 2021-07-01 Impact factor: 2.207